Superparamagnetic Particles Market Report 2026

The superparamagnetic particles market size has grown rapidly in recent years. It will grow from $1.38 billion in 2025 to $1.55 billion in 2026 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to medical imaging advancements, nanotechnology research growth, biomedical diagnostics demand, laboratory separation techniques, material science innovation.

The superparamagnetic particles market size is expected to see rapid growth in the next few years. It will grow to $2.43 billion in 2030 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to precision medicine adoption, advanced drug delivery systems, biosensor development, healthcare diagnostics expansion, nano medicine research funding. Major trends in the forecast period include rising use in mri contrast imaging, growing adoption in targeted drug delivery, expansion in magnetic separation techniques, increased focus on nano scale particle design, advancements in surface functionalization.

The growing demand for personalized medicine is expected to drive the expansion of the superparamagnetic particles market in the coming years. Personalized medicine refers to a medical approach that customizes treatment and healthcare decisions based on an individual’s genetic profile, lifestyle, and environment to enhance treatment outcomes and minimize side effects. The demand for personalized medicine is increasing due to advancements in genetic testing and precision diagnostics, which enable healthcare professionals to tailor therapies for each patient. Superparamagnetic particles play a key role in personalized medicine by supporting targeted drug delivery, molecular imaging, and diagnostic applications, ultimately contributing to improved therapeutic results. For instance, in February 2024, the Personalized Medicine Coalition, a United States-based non-profit organization, reported that in 2023, the United States Food and Drug Administration approved 16 new personalized treatments for patients with rare diseases, up from six in 2022, including seven cancer therapies and three for other medical conditions. Therefore, the growing demand for personalized medicine is driving the growth of the superparamagnetic particles market.

Key companies operating in the superparamagnetic particles market are focusing on developing advanced solutions, such as imaging agents, to enable non-invasive visualization of internal body structures. Imaging agents are substances that enhance the contrast of specific tissues or organs in medical imaging to improve diagnostic accuracy. For instance, in December 2023, Imagion Biosystems Limited, an Australia-based medical imaging company, announced positive outcomes following the completion of its IBI10103 phase I clinical trial. The study evaluated the safety and clinical feasibility of the MagSense HER2 Imaging Agent (MSH2IA) as an adjunct to MRI for detecting axillary lymph node metastasis in patients with HER2-positive primary breast cancer. This imaging agent is based on a core of superparamagnetic iron oxide nanoparticles produced at Imagion’s GMP-compliant facility in San Diego, California. The nanoparticles are coated with biocompatible polymers and conjugated to the monoclonal antibody trastuzumab (Herceptin). MSH2IA is administered as a single injection near the primary tumor site and travels through the lymphatic system, selectively binding to HER2-positive breast cancer cells to improve MRI visualization.

In July 2024, Hologic Inc., a United States-based medical technology company, acquired Endomagnetics Ltd. for 310 million dollars. Through this acquisition, Hologic aims to enhance and diversify its oncology portfolio by incorporating Endomagnetics Ltd’s magnetic surgical technologies, thereby strengthening its expertise in advanced cancer diagnostics, minimally invasive treatment solutions, and comprehensive patient care across multiple oncological fields. Endomagnetics Ltd. is a United Kingdom-based manufacturer of products containing superparamagnetic particles.

Major companies operating in the superparamagnetic particles market are Thermo Fisher Scientific Inc., Miltenyi Biotec B.V. & Co. KG, Spherotech Inc., nanoComposix Inc., Nanoshel LLC, Cytodiagnostics Inc., Micromod Partikeltechnologie GmbH, Ocean NanoTech LLC, MagQu Co. Ltd., Bang Laboratories, JSR Life Sciences LLC, BioVision Inc., Creative Diagnostics, Ademtech SAS, Chemicell GmbH, Bangs Laboratories Inc., NanoMagnetics Ltd., Sphere Fluidics Ltd., Fluidic Analytics Ltd., Bio-Rad Laboratories Inc., Bio-Nano Consulting Ltd.

North America was the largest region in the superparamagnetic particles market in 2025. The regions covered in the superparamagnetic particles market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the superparamagnetic particles market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The superparamagnetic particles market consists of sales of dynabeads, magnetic separators and racks, dextran-coated magnetic beads, magnetic hyperthermia nanoparticles, and silica-coated magnetic nanoparticles. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.